Results of the REDUCE trial show WL Gore & Associates Inc.'s septal occluders significantly reduce the chances of recurrent ischemic stroke in patients with a patent foramen ovale – commonly known as hole in the heart – and a history of stroke compared to antiplatelet therapy alone.
REDUCE compared the efficacy and safety of PFO-closure using Gore's Cardioform septal occluder or the earlier generation Helex septal occluder plus antiplatelet drugs to antiplatelet drug therapy alone in 664...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?